Tag Archives: CALM

Top 5 Clean Energy Stocks To Watch For 2021

Origami (CURRENCY:ORI) traded 2% higher against the U.S. dollar during the twenty-four hour period ending at 15:00 PM ET on July 2nd. One Origami token can now be purchased for $0.11 or 0.00001668 BTC on cryptocurrency exchanges including DDEX, IDEX and EtherDelta (ForkDelta). Origami has a market cap of $468,515.00 and $6,574.00 worth of Origami was traded on exchanges in the last day. During the last seven days, Origami has traded down 20.2% against the U.S. dollar.

Here is how related cryptocurrencies have performed during the last day:

Get Origami alerts:

XRP (XRP) traded up 6.2% against the dollar and now trades at $0.48 or 0.00007295 BTC. Ripple (XRP) traded down 4.6% against the dollar and now trades at $0.45 or 0.00007633 BTC. Stellar (XLM) traded up 7.5% against the dollar and now trades at $0.21 or 0.00003188 BTC. IOTA (MIOTA) traded up 12.1% against the dollar and now trades at $1.16 or 0.00017383 BTC. Tether (USDT) traded down 0.4% against the dollar and now trades at $1.00 or 0.00014982 BTC. TRON (TRX) traded 5.9% higher against the dollar and now trades at $0.0398 or 0.00000599 BTC. NEO (NEO) traded up 16.7% against the dollar and now trades at $36.07 or 0.00542635 BTC. Binance Coin (BNB) traded 0% higher against the dollar and now trades at $14.30 or 0.00215065 BTC. VeChain (VET) traded up 6.3% against the dollar and now trades at $2.74 or 0.00041280 BTC. Ontology (ONT) traded 4.8% higher against the dollar and now trades at $5.28 or 0.00079483 BTC.

Origami Token Profile

Top 5 Clean Energy Stocks To Watch For 2021: Coca-Cola Bottling Co. Consolidated(COKE)

Coca-Cola Bottling Co. Consolidated, incorporated on April 8, 1980, produces, markets and distributes nonalcoholic beverages, primarily products of The Coca-Cola Company, which include beverage brands. The Company is an independent Coca-Cola bottler in the United States. The Company’s segments are Nonalcoholic Beverages and All Other. The Company holds various agreements, under which it produces, distributes and markets sparkling beverages of The Coca-Cola Company, as well as still beverages of The Coca-Cola Company, such as POWERade, vitaminwater, Minute Maid Juices To Go and Dasani water products, and various other products, including Dr Pepper, Sundrop and Monster Energy products. Its operational footprint includes markets located in North Carolina, South Carolina, South Alabama, South Georgia, Central Tennessee, Western Virginia and West Virginia (the Legacy Territories). The Company also develops, markets and distributes certain products, which it owns, such as Tum-E Yummies, a vitamin-C enhanced flavored drink, and Fuel in a Bottle power shots.

The Company’s principal sparkling beverage is Coca-Cola. The Company offers a range of flavors to its consumers. In addition, the Company provides restaurants and other immediate consumption outlets with fountain or post-mix products. The Company holds various agreements with The Coca-Cola Company, which entitle the Company to produce, market and distribute in The Coca-Cola Company’s nonalcoholic beverages in bottles, cans and over five gallons pressurized pre-mix containers, in the Legacy Territories. The Company also has arrangements for the Company’s Legacy Territories with Dr Pepper Snapple Group, Inc. and other beverage companies for the Legacy Territories. The Company purchases concentrates from The Coca-Cola Company and produces, markets and distributes its principal sparkling beverages in the Legacy Territories under two forms of beverage agreements with The Coca-Cola Company: beverage agreements that cover sparkling beverages bearing! the trademark Coca-Cola or Coke (the Coca-Cola Trademark Beverages and Cola Beverage Agreements), and beverage agreements that cover other sparkling beverages of The Coca-Cola Company (the Allied Beverages and Allied Beverage Agreements).

Under the Allied Beverage Agreements, the Company has rights to distribute the Allied Beverages in authorized containers in specified Legacy Territories. The Company also purchases finished goods and distributes certain still beverages, such as sports drinks and juice drinks, from The Coca-Cola Company, or its designees or joint ventures, and produces, markets and distributes Dasani water products. The Company also sells Coca-Cola and other post-mix products of The Coca-Cola Company on a non-exclusive basis. The Company holds bottling rights in the Legacy Territories from The Coca-Cola Company covering North Carolina, South Carolina and West Virginia, and portions of Alabama, Mississippi, Tennessee, Kentucky, Illinois, Virginia, Pennsylvania, Georgia and Florida.

Advisors’ Opinion:

  • [By Logan Wallace]

    Coca-Cola Bottling Co. Consolidated (NASDAQ: COKE) and Coca Cola Femsa (NYSE:KOF) are both consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

  • [By Ethan Ryder]

    Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE) released its quarterly earnings data on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.88 by ($1.73), reports. Coca-Cola Bottling Co. Consolidated had a return on equity of 11.63% and a net margin of 2.23%.

Top 5 Clean Energy Stocks To Watch For 2021: Fluor Corporation(FLR)

Fluor Corporation, through its subsidiaries, provides engineering, procurement, construction, maintenance, and project management services worldwide. Its Oil & Gas segment offers design, engineering, procurement, construction, and project management services to upstream oil and gas production, downstream refining, chemicals, and petrochemicals industries. This segment also provides consulting services comprising feasibility studies, process assessment, and project finance structuring and studies. The company?s Industrial & Infrastructure segment offers design, engineering, procurement, and construction services to the transportation, wind power, mining and metals, life sciences, manufacturing, commercial and institutional, telecommunications, microelectronics, and healthcare sectors. Its Government segment provides engineering, construction, logistics support, contingency response, management, and operations services to the United States government focusing on the Departme nt of Energy, the Department of Homeland Security, and the Department of Defense. The company?s Global Services segment offers operations and maintenance, small capital project engineering and execution, site equipment and tool services, industrial fleet services, plant turnaround services, temporary staffing services, and supply chain solutions. Its Power segment provides engineering, procurement, construction, program management, start-up and commissioning, and operations and maintenance services to the gas fueled, solid fueled, plant betterment, renewables, nuclear, and power services markets. The company also offers unionized management and construction services in the United States and Canada. Fluor Corporation was founded in 1912 and is headquartered in Irving, Texas.

Advisors’ Opinion:

  • [By Joseph Griffin]

    Commonwealth Equity Services LLC decreased its holdings in shares of Fluor Co. (NEW) (NYSE:FLR) by 13.9% in the 4th quarter, Holdings Channel reports. The firm owned 81,055 shares of the construction company’s stock after selling 13,094 shares during the period. Commonwealth Equity Services LLC’s holdings in Fluor Co. (NEW) were worth $2,609,000 as of its most recent SEC filing.

  • [By Motley Fool Transcription]

    Fluor Corporation (NYSE:FLR) Q4 2018 Earnings Conference Call February 21, 2019, 5:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Lee Samaha]

    Shares of engineering and construction company Fluor(NYSE:FLR) were up 13.6% in January, according to data provided by S&P Global Market Intelligence. In the absence of any significant company news — its fourth-quarter earnings report is due on Feb. 21– the move can be attributed to a change in sentiment in the marketplace.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Fluor Co. (NEW) (FLR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Clean Energy Stocks To Watch For 2021: Foamix Pharmaceuticals Ltd.(FOMX)

Our legal and commercial name is Foamix Pharmaceuticals Ltd. (formerly Foamix Ltd.). We were incorporated as a limited liability company under the laws of the State of Israel on January 19, 2003. We are registered with the Israeli Registrar of Companies. Our registration number is 51-336881-1. Article 3 of our articles of association provides that our objectives are to conduct all types of business as are permitted by law. Our principal executive offices are located at 2 Holzman St., Weizmann Science Park, Rehovot 76704, Israel, and our telephone number is +972-8-9316233. Our website is www.foamixpharma.com. The information contained on, or that can be accessed through, our website does not constitute a part of this form and is not incorporated by reference herein. Foamix Pharmaceuticals Inc., our wholly-owned subsidiary, was incorporated on May 6, 2014 under the laws of the State of Delaware, with the intent to serve as our marketing and sales arm in the U.S.   Advisors’ Opinion:

  • [By Max Byerly]

    HC Wainwright set a $11.00 price target on Foamix Pharmaceuticals (NASDAQ:FOMX) in a research note released on Tuesday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

  • [By Joseph Griffin]

    Foamix Pharmaceuticals (NASDAQ:FOMX)’s stock had its “buy” rating reiterated by HC Wainwright in a report issued on Wednesday, MarketBeat reports. They currently have a $14.00 price objective on the specialty pharmaceutical company’s stock, up from their prior price objective of $12.00. HC Wainwright’s price objective would indicate a potential upside of 122.22% from the stock’s current price.

  • [By Chris Lange]

    Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) shares were last seen up early on Wednesday after the company announced a solid performance in its late-stage trial for moderate-to-severe acne.

Top 5 Clean Energy Stocks To Watch For 2021: Cal-Maine Foods, Inc.(CALM)

Cal-Maine Foods, Inc. produces, grades, packages, markets, and distributes shell eggs. It offers specialty shell eggs, such as nutritionally enhanced, cage free, organic, and brown eggs under the Egg-Lands Best, Land O Lake, Farmhouse, and 4-Grain brand names, as well as under private labels. The company sells its products to various customers, including national and regional grocery store chains, club stores, foodservice distributors, and egg product consumers primarily in the southeastern, southwestern, mid-western, and mid-Atlantic regions of the United States. Cal-Maine Foods, Inc. was founded in 1969 and is based in Jackson, Mississippi.

Advisors’ Opinion:

  • [By Garrett Baldwin]

    This morning, Chinese officials surprised markets with news that the nation’s manufacturing sector expanded last month. The Caixin/Markit Manufacturing Purchasing Managers’ Index (PMI) reading came in at 50.8, above the 49.9 figure expected by economists. A reading above 50 signals that the sector expanded from the previous month. Don’t forget about Brexit. Today, the British Parliament will hold a second round of votes on alternatives to the existing deal on the table from Prime Minister Theresa May. Last week, the governing body rejected a deal May negotiated with the European Union for the third time. The country has just two more weeks to reach a deal or it will crash out of the world’s largest trade bloc. That short deadline is made worse by the fact that the nation is no closer to a solution than it was more than 1,000 days ago, when voters decided to depart the European Union.
    Stocks to Watch Today: CALM, K, FB, AAPL
    There is no egg on the faces of Cal-Maine Foods Inc. (NASDAQ: CALM) executives this morning. The egg producers announced quarterly earnings per share of $0.82, well above Wall Street expectations at $0.43. The firm also beat revenue expectations and announced plans to expand its business.

    Act Now: Our new book could help you quadruple your monthly income, and we’re ready to send it to you immediately, for free – but only 1,000 copies are available today. Read more…

  • [By Max Byerly]

    Research analysts at Stephens assumed coverage on shares of Cal-Maine Foods (NASDAQ:CALM) in a report released on Monday, The Fly reports. The firm set an “equal weight” rating on the basic materials company’s stock.

  • [By Ethan Ryder]

    Shares of Cal-Maine Foods Inc (NASDAQ:CALM) have received an average rating of “Hold” from the six analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company.

  • [By Dan Caplinger]

    Monday was generally a good day for the stock market, although major benchmarks showed a considerable amount of variation in how they performed. The Dow Jones Industrial Average and S&P 500 seemed to benefit the most from news that the U.S., Mexico, and Canada had resolved their trade differences and come to a trilateral agreement, but the Nasdaq Composite lagged, and small-cap stocks posted substantial declines. Also hurting the overall market were some disturbing developments regarding some key companies. Infinera (NASDAQ:INFN), Akorn (NASDAQ:AKRX), and Cal-Maine Foods (NASDAQ:CALM) were among the worst performers on the day. Here’s why they did so poorly.

Top 5 Clean Energy Stocks To Watch For 2021: Vascular Biogenics Ltd.(VBLT)

Vascular Biogenics Ltd., incorporated on January 31, 2000, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule that demonstrated efficacy in reducing vascular inflammation in a Phase II sub-study in psoriatic patients with cardiovascular risk.

VTS Platform

The Company’s VTS platform technology enables systemic administration of gene therapy to either destroy or promote angiogenic blood vessels. VTS is both tissue- and condition-specific, allowing for targeted and limited gene expression in endothelial cells, the thin layer of cells that lines the interior surface of blood vessels undergoing angiogenesis. Its VTS platform technology comprises three components: a viral vector, a promoter and a transgene. The viral vector is a modified virus that is used as a delivery vehicle to distribute the promoter and the transgene throughout the body. The promoter is its genetically modified promoter, PPE-1-3X, which specifically targets the endothelial cells of angiogenic blood vessels. The transgene is a genetic sequence designed to yield a specific biologic effect, the expression of which is directed by PPE-1-3X.

The Company has studied VB-111 in a Phase I all comers trial involving patients with multiple types of metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma and lung cancer. In that trial, VB-111 was tolerated and showed a dose- dependent extension in median overall survival across a range of tumor types. Its VTS platform technology enables systemic administration of gene therapy to either destroy or promote angiogenic blood vessels. It has also generated additional product candidates, which utilize the same vector and promoter as in VB-111, and comprise alternative functional transgenes, which include VB-511, an anti-angiogenic candidate; VB-211 and VB-411, which are pro-angiogenic candidates that may be employed for ischemic conditions, such as peripheral vascular disease.

Lecinoxoid Platform

The Company’s Lecinoxoid platform technology comprises a family of orally administered small molecules designed to modulate the body’s inflammatory response. Lecinoxoids are compounds that are structurally and functionally similar to naturally occurring molecules, known as oxidized phospholipids, which possess immune modulating anti-inflammatory properties, modified to manage stability and activity. Its lead Lecinoxoid-based compound, VB-201, is designed as an oral agent for the control of chronic inflammatory disorders. VB-201 inhibits the CD-14/TLR4 and TLR2 pathways, as well as monocyte migration. The Company has also developed second and third generations of Lecinoxoid product candidates.

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    ReTo Eco-Solutions, Inc. (NASDAQ: RETO) fell 9.3 percent to $4.50 in pre-market trading.
    ProPhase Labs, Inc. (NASDAQ: PRPH) shares fell 8.5 percent to $4.50 in pre-market trading after dropping 3.53 percent on Thursday.
    Nordstrom, Inc. (NYSE: JWN) fell 7.5 percent to $47.10 in pre-market trading. Nordstrom reported upbeat results for its first quarter. Comparable-store sales rose 0.6 percent.
    Baidu, Inc. (NASDAQ: BIDU) shares fell 6 percent to $263.00 in pre-market trading. Baidu disclosed that its COO Qi Lu will step down in July 2018.
    Riot Blockchain, Inc. (NASDAQ: RIOT) shares fell 5.6 percent to $8.98 in pre-market trading after climbing 11.88 percent on Thursday.
    Applied Materials, Inc. (NASDAQ: AMAT) fell 5 percent to $51.30 in pre-market trading. Applied Materials reported stronger-than-expected results for its second quarter, but issued weak sales outlook for the third quarter.
    Blink Charging Co. (NASDAQ: BLNK) fell 5 percent to $7.61 in pre-market trading after rising 11.40 percent on Thursday.
    Illumina, Inc. (NASDAQ: ILMN) shares fell 4.7 percent to $255.77 in pre-market trading.
    Vascular Biogenics Ltd (NASDAQ: VBLT) fell 4.6 percent to $2.10 in pre-market trading after reporting a first-quarter earnings miss.
    Campbell Soup Company (NYSE: CPB) fell 3.3 percent to $37.60 in pre-market trading. Campbell Soup reported upbeat Q3 earnings, but sales missed estimates. The company also lowered its FY18 outlook.
    ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares fell 2.7 percent to $17.65 in pre-market trading after reporting a 7.2 million common stock offering

  • [By Lisa Levin] Companies Reporting Before The Bell
    Walmart Inc. (NYSE: WMT) is estimated to report quarterly earnings at $1.13 per share on revenue of $120.51 billion.
    J. C. Penney Company, Inc. (NYSE: JCP) is expected to report quarterly loss at $0.2 per share on revenue of $2.63 billion.
    Dillard's, Inc. (NYSE: DDS) is projected to report quarterly earnings at $2.77 per share on revenue of $1.46 billion.
    The Children's Place, Inc. (NASDAQ: PLCE) is estimated to report quarterly earnings at $2.21 per share on revenue of $444.14 million.
    Manchester United plc (NYSE: MANU) is expected to report quarterly loss at $1.35 per share on revenue of $193.67 million.
    Teekay Corporation (NYSE: TK) is estimated to report quarterly loss at $0.08 per share on revenue of $296.76 million.
    KEMET Corporation (NYSE: KEM) is projected to report quarterly earnings at $0.41 per share on revenue of $306.72 million.
    Vascular Biogenics Ltd. (NASDAQ: VBLT) is estimated to report a quarterly loss at $0.21 per share.
    Teekay Offshore Partners L.P. (NYSE: TOO) is expected to report quarterly earnings at $0.04 per share on revenue of $272.04 million.
    Albireo Pharma, Inc. (NASDAQ: ALBO) is expected to report quarterly earnings at $1.77 per share on revenue of $31.32 million.